Key facts
- Paratek Pharmaceuticals’s last known valuation is $490.9M (Sep 2023).
- It has raised $1.6B; the latest was Debt - Acquisition ($1.3B) in Mar 2026.
- Notable investors include Novo Holdings, B-FLEXION Life Sciences, REPAIR Impact Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Paratek Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Paratek Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Paratek Pharmaceuticals
Developer of antibacterial products intended to treat infectious diseases and improve patient outcomes. The company offers therapies based on advanced tetracycline chemistry, including omadacycline for pneumonia and skin infections, and sarecycline for acne and rosacea, enabling patients with bacterial and inflammatory conditions to achieve better clinical results and improved quality of life.
- Sector
- Healthcare
- HQ
- King of Prussia, PA, United States
- Founded
- 1996
- Employees
- 385
- Website
- paratekpharma.com/
- Ownership
- Privately Held (backing)
Paratek Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paratek Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paratek Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.